S urvival following cardiac transplantation has improved significantly with the advent of better immunosuppression therapy. In the current era, approximately 50% of patients survive more than 13 years, with an increasing population of patients surviving beyond 20 years (1). With the success of cardiac transplantation, older patients and those with comorbidities such as prior malignancy, diabetes, and renal insufficiency are now frequently treated with transplantation. This improvement in survival has subsequently increased the duration of immunosuppression therapy and, including the population of patients with significant co-morbidities, has resulted in the significant rise in de novo malignancies.

中文翻译：

---

心脏移植术后恶性肿瘤

随着更好的免疫抑制疗法的出现，心脏移植后的存活率显着提高。在当前时代，大约 50% 的患者存活超过 13 年，而且存活超过 20 年的患者人数不断增加 (1)。随着心脏移植的成功，老年患者和有合并症（如既往恶性肿瘤、糖尿病和肾功能不全）的患者现在经常接受移植治疗。这种生存率的提高随后增加了免疫抑制治疗的持续时间，并且包括具有显着合并症的患者群体，导致了新发恶性肿瘤的显着增加。